Last reviewed · How we verify
Liraglutide and metformin
Liraglutide and metformin is a GLP-1 receptor agonist + biguanide combination Small molecule drug developed by Peking University Third Hospital. It is currently FDA-approved for Type 2 diabetes mellitus.
Liraglutide stimulates insulin secretion via GLP-1 receptor activation while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.
Liraglutide stimulates insulin secretion via GLP-1 receptor activation while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Liraglutide and metformin |
|---|---|
| Sponsor | Peking University Third Hospital |
| Drug class | GLP-1 receptor agonist + biguanide combination |
| Target | GLP-1 receptor; metformin complex I inhibitor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Liraglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion and slows gastric emptying. Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. The combination provides complementary mechanisms to reduce hyperglycemia in type 2 diabetes mellitus.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Hypoglycemia
- Abdominal pain
Key clinical trials
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome (PHASE3)
- Liraglutide Effect in Atrial Fibrillation (PHASE4)
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes (NA)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Metabolic Surgery for Atrial Fibrillation Elimination (PHASE4)
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (PHASE4)
- HbA1c Variability in Type II Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liraglutide and metformin CI brief — competitive landscape report
- Liraglutide and metformin updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI
Frequently asked questions about Liraglutide and metformin
What is Liraglutide and metformin?
How does Liraglutide and metformin work?
What is Liraglutide and metformin used for?
Who makes Liraglutide and metformin?
What drug class is Liraglutide and metformin in?
What development phase is Liraglutide and metformin in?
What are the side effects of Liraglutide and metformin?
What does Liraglutide and metformin target?
Related
- Drug class: All GLP-1 receptor agonist + biguanide combination drugs
- Target: All drugs targeting GLP-1 receptor; metformin complex I inhibitor
- Manufacturer: Peking University Third Hospital — full pipeline
- Therapeutic area: All drugs in Endocrinology / Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: Liraglutide and metformin vs similar drugs
- Pricing: Liraglutide and metformin cost, discount & access